Risedronate Sodium Tablet, Film Coated
Product Images NDC 59762-0405

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 59762-0405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure Of Risedronate Sodium Hemi-pentahydrate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium For Oral Administration Contains The Equivalent Of 5, 30, 35, 75, Or 150 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium Tablets 01)

FDA Label Image

Figure 1 (Risedronate Sodium Tablets 02)

This is a chart showing the cumulative incidence of nonvertebral osteoporosis-related fractures over a period of 3 years for patients receiving either a placebo or risedronate sodium 5mg. The fractures are presented by location in the body such as leg, wrist, humerus, hip, pelvis, and clavicle.*

FDA Label Image

Figure 2 (Risedronate Sodium Tablets 03)

The given text represents a figure (Figure 2) depicting a "Change in BMD from Baseline" in a "2-Year Prevention Study". The study involved two treatment groups- Placebo and Risedronate Sodium 5mg with 103 and 101 participants, respectively. It shows the percentage change in Bone Mineral Density (BMD) measured at Lumbar Spine, Femoral Neck, and Femoral Trochanter. However, the numerical values seem to be corrupt or unreadable.*

FDA Label Image

Figure 3 (Risedronate Sodium Tablets 04)

This is a figure showing the change in bone mineral density (BMD) from baseline for patients who recently started glucocorticoid therapy. The BMD is represented in terms of mean percentage change along with standard error (SE). The figure shows the results for placebo, risedronate sodium 5 mg, and three other treatment groups. The treatment groups are labeled as Lo (Lumbar), an (neck), and eS (trochanter). The sample sizes (n) for each treatment group are also mentioned.*

FDA Label Image

Figure 4 (Risedronate Sodium Tablets 05)

The text appears to be an output of a table showing changes in Bone Mineral Density (BMD) from baseline for patients on long-term glucocorticoid therapy. It shows the BMD mean percentage change and standard error values for lumbar spine, femoral neck, and trochanter at different stages of the therapy for a group of patients who took either placebo or risedronate sodium 5 mg.*

FDA Label Image

Figure 5 (Risedronate Sodium Tablets 06)

FDA Label Image

Figure 6 (Risedronate Sodium Tablets 07)

This is a graph showing the mean percentage change from baseline in serum alkaline phosphatase excess by visit for two different treatments - DIDRONEL 400mg and Risedronate Sodium 30mg. It includes follow-up and extended follow-up visits up to 600 days.*

FDA Label Image

Greenstone (Risedronate Sodium Tablets 08)

The Greenstone® brand is distributed by Greenstone LLC located in Peapack, NJ 07977.*

FDA Label Image

Ndc 59762-0405-4risedronate Sodium Tablets35 mgonce-a-week4 Tabletsrx Only (Risedronate Sodium Tablets 0a)

This is a medication called Risedronate Sodium, available in tablet form at a strength of 35mg. The package seems to contain 4 tablets and may have been supplied by a company called "W & weoksuppy".*

FDA Label Image

Ndc 59762-0405-4risedronate Sodium Tablets35 mgonce-a-week4 Tabletsrx Only (Risedronate Sodium Tablets 0b)

This appears to be a list of medications, but the text is not fully legible due to errors. It is not possible to generate a useful description with this text.*

FDA Label Image

Ndc 59762-0405-5risedronate Sodium Tablets35 mg12 Week Supply12 (risedronate sodium tabletsRx only)

The text is not readable because of errors.*

FDA Label Image

Ndc 59762-0405-5risedronate Sodium Tablets35 mg12 Week Supply12 (risedronate sodium tabletsRx only)

FDA Label Image

Ndc 59762-0406-1risedronate Sodium Tablets150 mgone Month Pack(1 Tablet)rx Only (Risedronate Sodium Tablets 0e)

This appears to be a label for medication called "risedronate sodium tablets" made by Greenstones brand. It is not available.*

FDA Label Image

Ndc 59762-0406-1risedronate Sodium Tablets150 mgone Month Pack(1 Tablet)rx Only (Risedronate Sodium Tablets 0f)

The text is not-available as it consists of incomplete and unclear words/letters.*

FDA Label Image

Ndc 59762-0406-3risedronate Sodium Tablets150 mg3 Month Packrx Only (Risedronate Sodium Tablets 10)

Greenston's brand of risedronate sodium tablets is featured in the text along with some illegible characters.*

FDA Label Image

Ndc 59762-0406-3risedronate Sodium Tablets150 mg3 Month Packrx Only (Risedronate Sodium Tablets 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.